Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.
Jia Y, Han L, Ramage CL, Wang Z, Weng CC, Yang L, Colla S, Ma H, Zhang W, Andreeff M, Daver N, Jain N, Pemmaraju N, Bhalla K, Mustjoki S, Zhang P, Zheng G, Zhou D, Zhang Q, Konopleva M. Jia Y, et al. Among authors: mustjoki s. Haematologica. 2023 Oct 1;108(10):2626-2638. doi: 10.3324/haematol.2022.281915. Haematologica. 2023. PMID: 37078252 Free PMC article.
CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting.
Landberg N, von Palffy S, Askmyr M, Lilljebjörn H, Sandén C, Rissler M, Mustjoki S, Hjorth-Hansen H, Richter J, Ågerstam H, Järås M, Fioretos T. Landberg N, et al. Among authors: mustjoki s. Haematologica. 2018 Mar;103(3):447-455. doi: 10.3324/haematol.2017.169946. Epub 2017 Dec 28. Haematologica. 2018. PMID: 29284680 Free PMC article.
Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types.
Majumder MM, Leppä AM, Hellesøy M, Dowling P, Malyutina A, Kopperud R, Bazou D, Andersson E, Parsons A, Tang J, Kallioniemi O, Mustjoki S, O'Gorman P, Wennerberg K, Porkka K, Gjertsen BT, Heckman CA. Majumder MM, et al. Among authors: mustjoki s. Haematologica. 2020 Jun;105(6):1527-1538. doi: 10.3324/haematol.2019.217414. Epub 2019 Aug 22. Haematologica. 2020. PMID: 31439679 Free PMC article.
Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Hohtari H, Pallisgaard N, Kankainen M, Ellonen P, Brück O, Siitonen T, Säily M, Sinisalo M, Pyörälä M, Itälä-Remes M, Koskenvesa P, Elonen E, Mustjoki S, Porkka K. Hohtari H, et al. Among authors: mustjoki s. Haematologica. 2022 Aug 1;107(8):1971-1976. doi: 10.3324/haematol.2021.280578. Haematologica. 2022. PMID: 35484650 Free PMC article. No abstract available.
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia.
Kuusanmäki H, Dufva O, Vähä-Koskela M, Leppä AM, Huuhtanen J, Vänttinen I, Nygren P, Klievink J, Bouhlal J, Pölönen P, Zhang Q, Adnan-Awad S, Mancebo-Pérez C, Saad J, Miettinen J, Javarappa KK, Aakko S, Ruokoranta T, Eldfors S, Heinäniemi M, Theilgaard-Mönch K, Wartiovaara-Kautto U, Keränen M, Porkka K, Konopleva M, Wennerberg K, Kontro M, Heckman CA, Mustjoki S. Kuusanmäki H, et al. Among authors: mustjoki s. Blood. 2023 Mar 30;141(13):1610-1625. doi: 10.1182/blood.2021011094. Blood. 2023. PMID: 36508699 Free PMC article.
Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia.
Lundán T, Juvonen V, Mueller MC, Mustjoki S, Lakkala T, Kairisto V, Hochhaus A, Knuutila S, Porkka K. Lundán T, et al. Among authors: mustjoki s. Haematologica. 2008 Feb;93(2):178-85. doi: 10.3324/haematol.11910. Epub 2008 Jan 26. Haematologica. 2008. PMID: 18223279 Free article.
The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia.
Rajala HL, Olson T, Clemente MJ, Lagström S, Ellonen P, Lundan T, Hamm DE, Zaman SA, Lopez Marti JM, Andersson EI, Jerez A, Porkka K, Maciejewski JP, Loughran TP, Mustjoki S. Rajala HL, et al. Among authors: mustjoki s. Haematologica. 2015 Jan;100(1):91-9. doi: 10.3324/haematol.2014.113142. Epub 2014 Oct 3. Haematologica. 2015. PMID: 25281507 Free PMC article.
Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib.
Gullaksen SE, Skavland J, Gavasso S, Tosevski V, Warzocha K, Dumrese C, Ferrant A, Gedde-Dahl T, Hellmann A, Janssen J, Labar B, Lang A, Majeed W, Mihaylov G, Stentoft J, Stenke L, Thaler J, Thielen N, Verhoef G, Voglova J, Ossenkoppele G, Hochhaus A, Hjorth-Hansen H, Mustjoki S, Sopper S, Giles F, Porkka K, Wolf D, Gjertsen BT. Gullaksen SE, et al. Among authors: mustjoki s. Haematologica. 2017 Aug;102(8):1361-1367. doi: 10.3324/haematol.2017.167080. Epub 2017 May 18. Haematologica. 2017. PMID: 28522574 Free PMC article. Clinical Trial.
210 results